Premier Biomedical Launches Hemp Oil Based Topical Pain Relief Ointment


Premier Biomedical Launches Hemp Oil Based Topical Pain Relief Ointment
Jan 23, 2018
OTC Disclosure & News Service

JACKSON CENTER, Pa., Jan. 23, 2018 (GLOBE NEWSWIRE) — Premier Biomedical, Inc. (OTC:BIEI) announced introduction of a new hemp oil based topical ointment to complement its existing topical pain relief products, which include a 96-hour topical skin patch, oil-based and water-based roll-ons, and an oil-based spray. This two ounce jar ointment, along with the rest of Premier’s products, is made from all-natural, non-GMO, solvent- and pesticide-free ingredients. All of Premier’s pain relief products are available through their website,, select pharmacies, and, the largest mail-order pharmacy in the country.

William A. Hartman, President & CEO of Premier Biomedical, Inc., stated, “We are very excited that in our first 12 months of operation that we have been able to introduce five, very effective pain relieving products. That’s not just my assessment, but rather it is based on feedback and testimonials from our customers. Once people try our products, they will agree that they outperform every other competitive product in relieving pain and suffering, without the dangerous and addictive side-effects associated with opioids.”

For more information please contact:
William A. Hartman
President and CEO
Premier Biomedical, Inc.
Pain Relief Meds
(724) 633-7033

About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website:

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Source: Uptick Newswire

Primary Logo

Copyright © 2018 GlobeNewswire. All Rights Reserved